Personal information

No personal information available

Activities

Collapse all

Employment (1)

Wuhan Union Hospital Oncology Center: Wuhan, Hubei, CN

Employment
Source: Self-asserted source
Jing Tang

Education and qualifications (2)

Second Military Medical University: Shanghai, Shanghai, CN

PhD
Education
Source: Self-asserted source
Jing Tang

Huazhong University of Science and Technology: Wuhan, CN

Education
Source: Self-asserted source
Jing Tang

Funding (1)

氨基甲酰磷酸合成酶Ⅰ(CPS-I) 在原发性肝细胞癌转移过程中功能研究

2017-01-01 to 2019-12-31 | Grant
National Natural Science Foundation of China (Beijing, CN)
URL: https://app.dimensions.ai/details/grant/grant.8355092
GRANT_NUMBER: 81602107
Source: Self-asserted source
Jing Tang via DimensionsWizard

Works (21)

Data from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6879420.v2
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Data from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6879420
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27034144
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27034144.v1
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Tables 1-3 from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27034141
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Tables 1-3 from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27034141.v1
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Data from Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.c.6879420.v1
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Clinical Cancer Research
2023-10-13 | Journal article
DOI: 10.1158/1078-0432.CCR-22-2592
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304905
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304905.v1
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Tables 1-3 from Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304902
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

Supplementary Tables 1-3 from Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304902.v1
Contributors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu et al.
Source: check_circle
Crossref

A Molecular Hepatocellular Carcinoma Prognostic Score System Precisely Predicts Overall Survival of Hepatocellular Carcinoma Patients

Journal of Clinical and Translational Hepatology
2022-04-28 | Journal article
DOI: 10.14218/jcth.2021.00010
Part of ISSN: 2225-0719
Part of ISSN: 2310-8819
Source: Self-asserted source
Jing Tang
grade
Preferred source (of 2)‎

Discovery of a Carbamoyl Phosphate Synthetase 1–Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis

Hepatology
2021-12 | Journal article
DOI: 10.1002/hep.32088
Part of ISSN: 0270-9139
Part of ISSN: 1527-3350
Source: Self-asserted source
Jing Tang

Adipocyte-secreted microvesicle-derived miR-148a regulates adipogenic and osteogenic differentiation by targeting Wnt5a/Ror2 pathway

Life Sciences
2021-08 | Journal article
DOI: 10.1016/j.lfs.2021.119548
Part of ISSN: 0024-3205
Source: Self-asserted source
Jing Tang

Application of an optimized pharyngeal swab-assisted device in pharyngeal sampling for COVID-19 patients

Annals of Translational Medicine
2021-02 | Journal article
DOI: 10.21037/atm-20-3612
Part of ISSN: 2305-5839
Part of ISSN: 2305-5847
Source: Self-asserted source
Jing Tang

Cyclin K interacts with β-catenin to induce Cyclin D1 expression and facilitates tumorigenesis and radioresistance in lung cancer

Theranostics
2020 | Journal article
DOI: 10.7150/thno.42578
Part of ISSN: 1838-7640
Source: Self-asserted source
Jing Tang

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma

Theranostics
2020 | Journal article
DOI: 10.7150/thno.41616
Part of ISSN: 1838-7640
Source: Self-asserted source
Jing Tang

HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas

Genomics, Proteomics & Bioinformatics
2018-08-01 | Journal article
DOI: 10.1016/j.gpb.2018.07.003
Contributors: Qiuyu Lian; Shicheng Wang; Guchao Zhang; Dongfang Wang; Guijuan Luo; Jing Tang; Lei Chen; Jin Gu
Source: check_circle
Crossref

MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition

Cancer letters
2015-08-01 | Journal article
Source: Self-asserted source
Jing Tang

Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4

Gut
2014-02-26 | Journal article
Source: Self-asserted source
Jing Tang
How many people are using ORCID?